Within a few years, doctors will be able to remotely evaluate patients for their risk of developing Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia — without having to hook them up to expensive, cumbersome machines generally found only in hospitals. That’s the vision of Israeli entrepreneur Nathan…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is supporting efforts by pharmaceutical company Lundbeck to find a new way to diagnose Parkinson’s Disease patients earlier and more effectively. With a $1.3 million DKK (Danish krone) grant ($197,000 U.S.), Lundbeck plans to develop and validate a…
The discovery that abnormal cellular mechanisms are specific to distinct groups of sporadic Parkinson’s patients brings precision medicine for this neurodegenerative disorder one step closer to reality. A recent study suggests that identifying these individual disease differences and assessing neuroprotective treatments specific to each one is…
Two distinct proteins previously known to play key roles in the development of tremor associated with neurodegenerative diseases now have been found to interact directly, a discovery that might lead to new therapies for tremor-related movement disorders, including Parkinson’s disease. The study with that finding, “LINGO1 is a…
A non-contact boxing program could improve quality of life and willingness to exercise in people with Parkinson’s disease, new data shows. A preliminary study with these findings will be presented at the American Academy of Neurology‘s Annual Meeting, to be held in Toronto at the end of…
Enrollment in the Phase 1/2 PROPEL trial, evaluating the safety, tolerability, and early efficacy of PR001 — a one-time gene therapy — for Parkinson’s disease associated with mutations in the GBA1 gene, is progressing at two centers in New York and patient dosing is continuing. Prevail Therapeutics,…
The first patient has been dosed in a Phase 2 study testing NLY01, an investigational compound with a new mechanism of action designed to stall the progression of Parkinson’s disease. NLY01, being developed by Neuraly, could prevent nerve cell loss in the brain by stopping the…
To make it easier for Parkinson’s (PD) patients and healthy volunteers to take part in clinical trials, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is introducing a redesigned version of its Fox Trial Finder clinical study matching tool. “At the Foundation, our single urgent goal…
Tai chi improves motor function in people with mild to moderate Parkinson’s disease and may slow down disease progression, a new study has found. The study, “Tai Chi versus routine exercise in patients with early- or mild-stage Parkinson’s disease: a retrospective cohort analysis,” was published…
An investigational therapy known as NLX-112 (befiradol) may hold promise to treat levodopa-induced dyskinesia, a complication of long-term levodopa therapy that affects people with Parkinson’s disease, a study found. The study, “The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets,” was…
Get regular updates to your inbox.
